<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="proliferate">
            <roleset id="proliferate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="thing becoming abundant&#x09;&#x09;&#x09;&#x09;// gene products //&#x0A;" />
                    <role n="1" descr="situation of becoming abundant&#x0A;" />
                    <role n="2" descr="location referring to organ, vitro&#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>Adult naive T cells are able to regain the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Adult naive T cells are able to regain the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Adult naive T cells are observed to regain the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Adult naive T cells are observed to regain the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Adult naive T cells can regain the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Adult naive T cells can regain the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Adult naive T cells have regained the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Adult naive T cells have regained the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Adult naive T cells have the probability of regaining the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Adult naive T cells have the probability of regaining the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Adult naive T cells may have regained the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Adult naive T cells may have regained the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Adult naive T cells regain the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Adult naive T cells regained the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Adult naive T cells regained the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Adult naive T cells will regain the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Adult naive T cells will regain the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells are able to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells are observed to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells being able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells being observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells can cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells ceasing to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells have ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells have the ability to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells having ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells having the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells may cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that are observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that can cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that ceased to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that have ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that have the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that may cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells that will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>After androgen withdrawal and antiandrogen treatment, Cancer cells will cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">Cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Further, HSC are able to be found to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Further, HSC are able to be observed to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Further, HSC are able to be proven to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Further, HSC could be found to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Further, HSC could be induced to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Further, HSC could be observed to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Further, HSC could be proven to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Further, HSC have been found to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Further, HSC have been found to strongly proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Further, HSC have been observed to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Further, HSC have been observed to strongly proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Further, HSC have been proven to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Further, HSC have been proven to strongly proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>HIV-specific CD4+ T cells of viremic patients can continue to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>HIV-specific CD4+ T cells of viremic patients can continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>HIV-specific CD4+ T cells of viremic patients continued to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>HIV-specific CD4+ T cells of viremic patients has continued to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>HIV-specific CD4+ T cells of viremic patients has continued to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>HIV-specific CD4+ T cells of viremic patients has the ability to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>HIV-specific CD4+ T cells of viremic patients has the ability to continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>HIV-specific CD4+ T cells of viremic patients has the probability of continuing to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>HIV-specific CD4+ T cells of viremic patients has the probability of continuing to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>HIV-specific CD4+ T cells of viremic patients is able to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>HIV-specific CD4+ T cells of viremic patients is able to continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>HIV-specific CD4+ T cells of viremic patients is observed to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>HIV-specific CD4+ T cells of viremic patients is observed to continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>HIV-specific CD4+ T cells of viremic patients may have continued to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>HIV-specific CD4+ T cells of viremic patients may have continued to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>HIV-specific CD4+ T cells of viremic patients will continue to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>HIV-specific CD4+ T cells of viremic patients will continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells of viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibody</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Our observations illustrate that Adult naive T cells can be endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Our observations illustrate that Adult naive T cells can be endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Our observations illustrate that Adult naive T cells has been endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Our observations illustrate that Adult naive T cells has been endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Our observations illustrate that Adult naive T cells has the ability to be endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>Our observations illustrate that Adult naive T cells has the ability to be endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>Our observations illustrate that Adult naive T cells is able to be endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>Our observations illustrate that Adult naive T cells is able to be endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>Our observations illustrate that Adult naive T cells is endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>Our observations illustrate that Adult naive T cells is shown to be endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>Our observations illustrate that Adult naive T cells is shown to be endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>Our observations illustrate that Adult naive T cells may have been endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>Our observations illustrate that Adult naive T cells may have been endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>Our observations illustrate that Adult naive T cells was endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>Our observations illustrate that Adult naive T cells was endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>Our observations illustrate that Adult naive T cells will be endowed with the biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>Our observations illustrate that Adult naive T cells will be endowed with the biochemical machinery to proliferate when transferred to lymphopenic hosts, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has been endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has been endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has the ability to be endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has the ability to be endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is able to be endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is able to be endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is shown to be endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is shown to be endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells may have been endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells may have been endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells was endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells was endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells will be endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells will be endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>Our observations illustrate that endothelial cells can be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>Our observations illustrate that endothelial cells can be endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>Our observations illustrate that endothelial cells has been endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>Our observations illustrate that endothelial cells has been endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>Our observations illustrate that endothelial cells has the ability to be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>Our observations illustrate that endothelial cells has the ability to be endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>Our observations illustrate that endothelial cells is able to be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>Our observations illustrate that endothelial cells is able to be endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>Our observations illustrate that endothelial cells is endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>Our observations illustrate that endothelial cells is shown to be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>Our observations illustrate that endothelial cells is shown to be endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>Our observations illustrate that endothelial cells may have been endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>Our observations illustrate that endothelial cells may have been endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>Our observations illustrate that endothelial cells was endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>Our observations illustrate that endothelial cells was endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>Our observations illustrate that endothelial cells will be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>Our observations illustrate that endothelial cells will be endowed with the biochemical machinery to proliferate when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are able to proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are able to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, can proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, can proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, can strongly proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, could have proliferated strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, could have proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, could have strongly proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have strongly proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, may proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, may proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, may strongly proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, might have proliferated strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, might have proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, might have strongly proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, proliferated strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, proliferated upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate strongly upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will strongly proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can significantly impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has impaired their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has significantly impaired their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to significantly impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impaired their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impairs their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to significantly impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, significantly impaired their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will significantly impair their capacity to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">Adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has impaired their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has significantly impaired their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impaired their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impairs their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, significantly impaired their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">upon introduction of full-length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can significantly impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has impaired their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has significantly impaired their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to significantly impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impaired their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impairs their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to significantly impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, significantly impaired their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will significantly impair their capacity to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>endothelial cells are able to regain the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>endothelial cells are able to regain the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>endothelial cells are observed to regain the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>endothelial cells are observed to regain the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>endothelial cells can regain the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>endothelial cells can regain the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>endothelial cells have regained the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>endothelial cells have regained the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>endothelial cells have the probability of regaining the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>endothelial cells have the probability of regaining the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>endothelial cells may have regained the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>endothelial cells may have regained the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>endothelial cells regain the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>endothelial cells regained the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>endothelial cells regained the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>endothelial cells will regain the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>endothelial cells will regain the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>endothelial cells, which are at rest in normal conditions, are able to proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>endothelial cells, which are at rest in normal conditions, are able to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>endothelial cells, which are at rest in normal conditions, are observed to proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>endothelial cells, which are at rest in normal conditions, are observed to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>endothelial cells, which are at rest in normal conditions, can proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>endothelial cells, which are at rest in normal conditions, can proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>endothelial cells, which are at rest in normal conditions, can strongly proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>endothelial cells, which are at rest in normal conditions, could have proliferated strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>endothelial cells, which are at rest in normal conditions, could have proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>endothelial cells, which are at rest in normal conditions, could have strongly proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>endothelial cells, which are at rest in normal conditions, have proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>endothelial cells, which are at rest in normal conditions, have strongly proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>endothelial cells, which are at rest in normal conditions, have the ability to proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>endothelial cells, which are at rest in normal conditions, have the ability to proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>endothelial cells, which are at rest in normal conditions, may proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>endothelial cells, which are at rest in normal conditions, may proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>endothelial cells, which are at rest in normal conditions, may strongly proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>endothelial cells, which are at rest in normal conditions, might have proliferated strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>endothelial cells, which are at rest in normal conditions, might have proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>endothelial cells, which are at rest in normal conditions, might have strongly proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>endothelial cells, which are at rest in normal conditions, proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>endothelial cells, which are at rest in normal conditions, proliferated strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>endothelial cells, which are at rest in normal conditions, proliferated when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>endothelial cells, which are at rest in normal conditions, will proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>endothelial cells, which are at rest in normal conditions, will proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>endothelial cells, which are at rest in normal conditions, will strongly proliferate when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>the androgen responsive prostate cancer cells are believed to be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>the androgen responsive prostate cancer cells are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>the androgen responsive prostate cancer cells are characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>the androgen responsive prostate cancer cells are characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>the androgen responsive prostate cancer cells are characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>the androgen responsive prostate cancer cells can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>the androgen responsive prostate cancer cells can be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>the androgen responsive prostate cancer cells has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>the androgen responsive prostate cancer cells has been characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>the androgen responsive prostate cancer cells may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>the androgen responsive prostate cancer cells may be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>the androgen responsive prostate cancer cells was characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>the androgen responsive prostate cancer cells was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>the androgen responsive prostate cancer cells wil be characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>the androgen responsive prostate cancer cells wil be characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">the androgen responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>the human placenta are able to regain the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>the human placenta are able to regain the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>the human placenta are observed to regain the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>the human placenta are observed to regain the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>the human placenta can regain the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>the human placenta can regain the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>the human placenta have regained the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>the human placenta have regained the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>the human placenta have the probability of regaining the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>the human placenta have the probability of regaining the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>the human placenta may have regained the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>the human placenta may have regained the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>the human placenta regain the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>the human placenta regained the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>the human placenta regained the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>the human placenta will regain the ability to proliferate indefinitely throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>the human placenta will regain the ability to proliferate throughout gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>the human placenta, which are at rest in normal conditions, are able to proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>the human placenta, which are at rest in normal conditions, are able to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>the human placenta, which are at rest in normal conditions, are observed to proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>the human placenta, which are at rest in normal conditions, are observed to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>the human placenta, which are at rest in normal conditions, can proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>the human placenta, which are at rest in normal conditions, can proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>the human placenta, which are at rest in normal conditions, can strongly proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>the human placenta, which are at rest in normal conditions, could have proliferated strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>the human placenta, which are at rest in normal conditions, could have proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>the human placenta, which are at rest in normal conditions, could have strongly proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>the human placenta, which are at rest in normal conditions, have proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>the human placenta, which are at rest in normal conditions, have strongly proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>the human placenta, which are at rest in normal conditions, have the ability to proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>the human placenta, which are at rest in normal conditions, have the ability to proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>the human placenta, which are at rest in normal conditions, may proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>the human placenta, which are at rest in normal conditions, may proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>the human placenta, which are at rest in normal conditions, may strongly proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>the human placenta, which are at rest in normal conditions, might have proliferated strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>the human placenta, which are at rest in normal conditions, might have proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>the human placenta, which are at rest in normal conditions, might have strongly proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>the human placenta, which are at rest in normal conditions, proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>the human placenta, which are at rest in normal conditions, proliferated strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>the human placenta, which are at rest in normal conditions, proliferated throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>the human placenta, which are at rest in normal conditions, will proliferate strongly throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>the human placenta, which are at rest in normal conditions, will proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>the human placenta, which are at rest in normal conditions, will strongly proliferate throughout gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">throughout gestation</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells are able to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells are observed to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells being able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells being observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells can cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells ceasing to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells have ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells have the ability to cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells having ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells having the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells may cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that are observed to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that can cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that ceased to proliferate and underwent apoptosis caused tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that have ceased to proliferate and undergo apoptosis caused tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that have the ability to cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that may cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells will cease to proliferate and undergo apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>intrasplenically transplanted fetal liver cells are believed to be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>intrasplenically transplanted fetal liver cells are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>intrasplenically transplanted fetal liver cells are characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>intrasplenically transplanted fetal liver cells are characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>intrasplenically transplanted fetal liver cells are characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>intrasplenically transplanted fetal liver cells can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>intrasplenically transplanted fetal liver cells can be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>intrasplenically transplanted fetal liver cells has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>intrasplenically transplanted fetal liver cells has been characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>intrasplenically transplanted fetal liver cells may be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>intrasplenically transplanted fetal liver cells may be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>intrasplenically transplanted fetal liver cells was characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>intrasplenically transplanted fetal liver cells was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>intrasplenically transplanted fetal liver cells wil be characterized by either an increased ability for proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>intrasplenically transplanted fetal liver cells wil be characterized by either an increased ability for strong proliferating or a diminished capacity to undergo programmed cell death.</text>
                    <arg n="0">intrasplenically transplanted fetal liver cells</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
